/4553.T
4553.T Stock - Towa Pharmaceutical Co., Ltd.
Healthcare|Drug Manufacturers - Specialty & GenericJPX
$3745.00+1.90%
+$70.00 (+1.90%) • Dec 23
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.92
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $4119.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for 4553.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3707.55 – $3782.45
TARGET (TP)$4306.75
STOP LOSS$3445.40
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.33
52W High$3750.00
52W Low$2298.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $259.59B | $227.93B | $208.86B | $165.62B | $154.90B |
| Gross Profit | $94.73B | $81.38B | $72.71B | $70.19B | $65.45B |
| Gross Margin | 36.5% | 35.7% | 34.8% | 42.4% | 42.3% |
| Operating Income | $23.24B | $17.65B | $5.51B | $19.20B | $19.92B |
| Net Income | $18.99B | $16.17B | $2.20B | $15.91B | $13.96B |
| Net Margin | 7.3% | 7.1% | 1.1% | 9.6% | 9.0% |
| EPS | $385.70 | $328.58 | $44.72 | $323.35 | $283.62 |
Company Overview
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
4553.TBeat Rate
56%
Last 18 quarters
Avg Surprise
+42.7%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$115.81
Q4 2025
EPS Surprise History
Q1 24
+226.1%
$92.77vs$28.45
Q2 24
+144.6%
$94.56vs$38.66
Q3 24
+113.5%
$111.64vs$52.30
Q4 24
-56.6%
$21.53vs$49.62
Q1 25
+184.3%
$163.91vs$57.66
Q2 25
-22.2%
$88.61vs$113.89
Q3 25
-19.6%
$51.05vs$63.46
Q4 25
+86.7%
$115.81vs$62.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 5, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | $62.02 | $115.81 | +86.7% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $63.46 | $51.05 | -19.6% | ✗ MISS |
Q2 2025 | May 15, 2025 | $113.89 | $88.61 | -22.2% | ✗ MISS |
Q1 2025 | Feb 11, 2025 | $57.66 | $163.91 | +184.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $49.62 | $21.53 | -56.6% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $52.30 | $111.64 | +113.5% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $38.66 | $94.56 | +144.6% | ✓ BEAT |
Q1 2024 | Feb 13, 2024 | $28.45 | $92.77 | +226.1% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $24.38 | $44.75 | +83.6% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $22.00 | $96.51 | +338.7% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $37.00 | $4.41 | -88.1% | ✗ MISS |
Q1 2023 | Feb 13, 2023 | $88.00 | $-14.38 | -116.3% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $55.00 | $26.35 | -52.1% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $84.00 | $28.34 | -66.3% | ✗ MISS |
Q2 2022 | May 13, 2022 | $53.00 | $18.57 | -65.0% | ✗ MISS |
Q1 2022 | Feb 14, 2022 | $112.00 | $117.01 | +4.5% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $79.00 | $79.88 | +1.1% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $63.00 | $107.92 | +71.3% | ✓ BEAT |
Q2 2021 | May 14, 2021 | — | $91.66 | — | — |
Latest News
Loading news...
Frequently Asked Questions about 4553.T
What is 4553.T's current stock price?
Towa Pharmaceutical Co., Ltd. (4553.T) is currently trading at $3745.00 per share. The stock has moved +1.90% today.
What is the analyst price target for 4553.T?
No analyst price targets are currently available for this stock.
What sector is Towa Pharmaceutical Co., Ltd. in?
Towa Pharmaceutical Co., Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the JPX exchange.
What is 4553.T's market cap?
Towa Pharmaceutical Co., Ltd. has a market capitalization of $184.36 billion, making it a large-cap company.
Does 4553.T pay dividends?
No, Towa Pharmaceutical Co., Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare Sector2160.T
GNI Group Ltd.
$2400.00
Mkt Cap: $133.4B
4516.T
Nippon Shinyaku Co., Ltd.
$5841.00
Mkt Cap: $393.7B
4521.T
Kaken Pharmaceutical Co., Ltd.
$4090.00
Mkt Cap: $154.9B
4534.T
Mochida Pharmaceutical Co., Ltd.
$3425.00
Mkt Cap: $121.4B
4547.T
Kissei Pharmaceutical Co., Ltd.
$4635.00
Mkt Cap: $192.1B
4559.T
Zeria Pharmaceutical Co., Ltd.
$2115.00
Mkt Cap: $93.2B
4569.T
KYORIN Holdings, Inc.
$1547.00
Mkt Cap: $88.9B
4694.T
BML, Inc.
$3890.00
Mkt Cap: $150.9B
6523.T
PHC Holdings Corporation
$1126.00
Mkt Cap: $142.5B
7730.T
Mani, Inc.
$1467.00
Mkt Cap: $144.5B
Explore stocks similar to 4553.T for comparison